Unlocking Biotech Innovation: Lessons from opnMe and the Power of Open Collaboration
June 19, 2025 —In today’s rapidly evolving biotechnology landscape, the need for effective collaboration between academia and industry has never been greater. The story of opnMe, an open innovation platform launched by UIDP member Boehringer Ingelheim, offers a prime example of how open science and collaboration can accelerate progress, not just in drug discovery, but as an overall approach to university-industry (U-I) partnerships.
In much the same way the Structural Genomics Consortium (see this 3-Minute Read) leverages open science to offer its human proteins discoveries to the public, opnMe’s diverse array of pre-clinical compounds could fast-track R&D for new biotech companies and prove a fruitful resource for the tech transfer community.
Open Science in Action: A Model for the Future
opnMe provides access to high-quality molecular compounds and collaborative opportunities for scientific researchers worldwide. What differentiates opnMe is a commitment to accelerating drug discovery by making these compounds available to researchers free of charge. The “no IP strings” intellectual property model is also distinctive; all discovery and IP generated with the molecules is owned by the scientist who used the opnMe molecules. This approach fosters innovation and creates a collaborative environment where academia, industry, and startups can converge to explore new frontiers in medicine and accelerate discovery. Scientists are also invited to submit research collaboration proposals addressing precisely formulated pharmacological (“opn2EXPERTS”) or technological (“techMATCH”) questions that have been shared by scientists from Boehringer Ingelheim.
Overcoming Barriers, Accelerating Discovery
One of the most significant challenges in U-I partnerships is navigating the complexities of IP and access to resources. opnMe’s “Molecules to Order” program addresses this by providing transparent IP management. Early exchanges include only non-confidential data, but as collaboration progresses, the platform offers ways to confidentially share proprietary information. Scientists using opnMe compounds retain IP for any new therapeutic claims they discover, and collaboration agreements outline each party’s rights and obligations. This makes it easier for tech transfer offices to engage with a large pharmaceutical partner, reducing negotiation challenges and accelerating innovations. If a collaboration with Boehringer Ingelheim goes forward, formal discussions on IP specifics related to funded research will follow.
Collaboration in Action: Success Stories
Collaborations initiated through the platform have led to breakthroughs in areas like lung adenocarcinoma, where academia and industry teams worked together to overcome drug resistance and improve treatment outcomes.[1,2]
These collaborative partnerships have advanced drug formulation and preclinical safety studies, demonstrating how open resources drive scientific breakthroughs.
Beyond academia, opnMe has also enabled successful collaborations with small- to mid-sized companies in emerging fields such as nanoformulation and artificial intelligence. For example, partnerships have addressed challenges that have led to new research directions and expanded capabilities for both the biotech firms and Boehringer Ingelheim’s teams. Collaborations have also resulted in the development of advanced software tools that enhance the efficiency and accuracy of preclinical safety studies, ultimately contributing to faster and safer drug development. These examples highlight how opnMe’s open innovation model supports scientific progress by bringing together diverse expertise and resources.
Why it matters
Since its launch, opnMe has shipped more than 8,000 molecules and received nearly 2,500 research collaboration proposals from scientists from 72 countries. This scale highlights the platform’s ability to bring together stakeholders from universities, startups, and companies to collaborate and solve real-world challenges. To learn more, researchers, biotech/startup companies, and university tech transfer professionals are invited to participate in the latest opn2EXPERTS collaboration call on “Improved Control of Impulsivity and Compulsivity” through July 8, which has been shared by opnMe and Boehringer’s Neuroscience & Mental Health Discovery Research department.
Thank you to Menorca Chaturvedi and Tamara Reeh of Boehringer Ingelheim for contributing the insights in this week’s 3-Minute Read.
We want to hear from you. How is your organization leveraging open science? Let us know on LinkedIn.
The 3-Minute Read is a UIDP member information piece and does not represent the opinions of our members or representatives. We welcome your comments on our LinkedIn profile.